HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Kenneth A. Kesler Karen M. Rieger Zane T. Hammoud Mark W. Turrentine John W. Brown Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kesler, K. A. Articles by Brown, J. W. Search for Related Content PubMed Articles by Kesler, K. A. Articles by Brown, J. W. Related Collections Mediastinum

---

Original Articles: General Thoracic

A 25-Year Single Institution Experience With Surgery for Primary Mediastinal Nonseminomatous Germ Cell Tumors

^a Department of Surgery, Cardiothoracic Division, Indiana University School of Medicine, Indianapolis, Indiana
^b Department of Medicine, Biostatistics Division, Indiana University School of Medicine, Indianapolis, Indiana
^c Department of Medicine, Oncology Division, Indiana University School of Medicine, Indianapolis, Indiana

Accepted for publication September 13, 2007.

^_* Address correspondence to Dr Kesler, Indiana University Department of Surgery, Cardiothoracic Division, Barnhill Drive EM #212, Indianapolis, IN 46202 (Email: kkesler{at}iupui.edu).

Background: The treatment of primary mediastinal nonseminomatous germ cell tumors (PMNSGCT) with cisplatin-based chemotherapy, followed by surgical resection of residual disease, has been established. We reviewed our institution’s 25-year experience in the cisplatin era to determine surgical risks and predictors of survival after surgery for PMNSGCT.

Methods: A total of 158 patients (mean age, 29 ± 8 years) who underwent postchemotherapy operations for PMNSGCT were reviewed and multiple variables analyzed.

Results: Ten (6%) operative deaths occurred, nine of which were attributed to respiratory failure, and 26 (18%) patients experienced postoperative complications, including 9 with respiratory failure. None of 17 recent patients who received chemotherapy regimens that did not contain bleomycin experienced pulmonary complications (p = 0.12 vs patients who received bleomycin). Operative survivors were followed up a median of 34 months (range, 1 to 194 months). Multivariable analysis demonstrated that the postchemotherapy pathologic category of complete necrosis vs teratoma), persistent germ cell or nongerm cell cancer, and elevated serum tumor markers after operation were independently predictive of survival.

Conclusions: Operative risks for PMNSGCT appear to be improved with the use of chemotherapy regimens that do not contain bleomycin. Patients pathologically demonstrating complete tumor necrosis in the residual mass after chemotherapy have excellent long-term survival, with decreasing survival after resection of teratoma and persistent germ cell or nongerm cell cancer. Patients pathologically demonstrating persistent germ cell or nongerm cell cancer have poor but possible long-term survival, which justifies an aggressive surgical approach in patients who are deemed operable.